{"id":"https://openalex.org/W1782669727","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011","title":"Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)","display_name":"Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)","alternate_titles":[],"publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W1782669727","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011","mag":"1782669727"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.lba4011","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1782669727"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043942519","display_name":"Cornelis J.A. Punt","orcid":"https://orcid.org/0000-0003-0846-1445","observed_orcids":["https://orcid.org/0000-0003-0846-1445","https://orcid.org/0000-0003-4196-4896"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C. J. Punt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074552728","display_name":"Johanna A.M.G. Tol","orcid":"https://orcid.org/0000-0002-9684-7825","observed_orcids":["https://orcid.org/0000-0002-9684-7825"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Tol","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036306758","display_name":"Cees J. Rodenburg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C. J. Rodenburg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109957754","display_name":"Anemieke Cats","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Cats","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113620018","display_name":"G. J. M. Creemers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Creemers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109520021","display_name":"Jolanda G. Schrama","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. G. Schrama","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111777532","display_name":"F. Erdkamp","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. L. Erdkamp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052204929","display_name":"Allert H. Vos","orcid":"https://orcid.org/0009-0002-4028-8371","observed_orcids":["https://orcid.org/0009-0002-4028-8371"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Vos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086479144","display_name":"Linda Mol","orcid":"https://orcid.org/0000-0002-4155-1605","observed_orcids":["https://orcid.org/0000-0002-4155-1605"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L. Mol","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5018297153","display_name":"Ninja F. Antonini","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. F. Antonini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":138,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"LBA4011","last_page":"LBA4011"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-colorectal-cancer","display_name":"advanced colorectal cancer","score":0.9819999933242798},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9520000219345093},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":1.0},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/egfr-inhibition","display_name":"EGFR inhibition","score":0.7289999723434448},{"id":"https://openalex.org/keywords/vegf-inhibition","display_name":"VEGF inhibition","score":0.9679999947547913},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7760000228881836},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.921999990940094},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6179999709129333},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6019999980926514},{"id":"https://openalex.org/keywords/anti-egfr-monoclonal-antibody","display_name":"anti-EGFR monoclonal antibody","score":0.33500000834465027},{"id":"https://openalex.org/keywords/anti-vegf-antibody","display_name":"anti-VEGF antibody","score":0.6579999923706055},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.5699999928474426}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.926651120185852},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9176294803619385},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8741887807846069},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.8190097808837891},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.7389053702354431},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6746075749397278},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.645180344581604},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5901341438293457},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5834469795227051},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.471332311630249},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.42314815521240234},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4022712707519531},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3529454469680786},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3206222653388977},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22123220562934875},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.21230557560920715}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.lba4011","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2110920272","https://openalex.org/W2133505009","https://openalex.org/W2042671096","https://openalex.org/W2061416514","https://openalex.org/W1918801206","https://openalex.org/W2476532096","https://openalex.org/W2088041819","https://openalex.org/W2287177543","https://openalex.org/W2883748520","https://openalex.org/W2127640925"],"abstract_inverted_index":{"LBA4011":[0],"Background:":[1],"Cetuximab,":[2],"a":[3,28,195,425],"chimaeric":[4],"monoclonal":[5],"antibody":[6],"against":[7],"the":[8,46,90,141,155,215,454],"epidermal":[9],"growth":[10],"factor":[11],"receptor":[12],"(EGFR)":[13],"has":[14],"shown":[15],"efficacy":[16],"in":[17,37,58,98,140,154,204,211,250,257,270,284,300,349,354,364,372,424,428,460],"patients":[18,190,230],"(pts)":[19],"with":[20,194,228],"ACC.":[21,38,59],"Preclinical":[22],"and":[23,33,53,56,80,103,170,182,207,246,253,274,290,332,352,367,406,419,433,446],"early":[24],"clinical":[25],"studies":[26],"suggest":[27],"benefit":[29],"for":[30,236,262],"combining":[31],"VEGF":[32],"EGFR":[34],"targeting":[35],"agents":[36],"The":[39,118,132,413],"CAIRO2":[40],"study":[41,133],"was":[42,121,126,134,359],"designed":[43,135],"to":[44,51,136,149,421,431,444,462,470],"investigate":[45],"effect":[47],"of":[48,144,158,164,198,200,217,238,248,255,264,341,415,464],"adding":[49],"cetuximab":[50,94,418,438],"capecitabine":[52,67],"oxaliplatin":[54,74],"(CapOx)":[55],"bevacizumab":[57,81,432],"Methods:":[60],"Previously":[61],"untreated":[62],"pts":[63,249,256],"were":[64,113,177,305,346,384],"randomized":[65,178],"between":[66,179,243],"1000":[68],"mg/m\u00b2":[69,76,96,105],"orally":[70],"b.i.d.":[71],"day":[72,78,85],"1\u201314,":[73],"130":[75],"i.v.":[77,84,97,106],"1,":[79,100,102],"7.5":[82],"mg/kg":[83],"1":[86],"(arm":[87,109,272,276,288,292],"A)":[88,273,289],"or":[89,344],"same":[91],"schedule":[92],"plus":[93],"400":[95],"week":[99],"cycle":[101],"250":[104],"weekly":[107],"thereafter":[108],"B).":[110],"All":[111],"cycles":[112,130,199],"given":[114],"q":[115,128],"3":[116,129,145],"weeks.":[117],"primary":[119],"endpoint":[120],"progression-free":[122],"survival":[123],"(PFS).":[124],"Response":[125,379],"assessed":[127],"(RECIST).":[131],"detect":[137],"an":[138],"increase":[139],"median":[142,171,196,220,394],"PFS":[143,358,429],"months":[146,151,224,361,369,399,402],"from":[147],"11":[148],"14":[150],"(21%":[152],"reduction":[153],"hazard":[156],"ratio":[157],"progression,":[159],"HR=0.79)":[160],"Results:":[161],"A":[162,206,252,302,339,351,366],"total":[163,340],"755":[165],"patients,":[166],"WHO":[167],"PS":[168],"0\u20131":[169],"age":[172],"62":[173],"yrs":[174],"(range":[175,202,209,225],"27\u201383),":[176],"June":[180],"2005":[181],"December":[183],"2006.":[184],"Of":[185],"736":[186],"eligible":[187],"pts,":[188],"730":[189],"started":[191],"protocol":[192],"treatment":[193,239,244,261],"number":[197],"10":[201],"1\u201339)":[203],"arm":[205,212,251,258,301,350,355,365,373],"9":[208],"1\u201340)":[210],"B.":[213,356],"At":[214],"time":[216],"this":[218],"analysis,":[219],"follow-up":[221],"is":[222],"14.7":[223],"4\u201328":[226],"months)":[227],"140":[229],"(19%)":[231],"still":[232],"receiving":[233],"treatment.":[234,465],"Reasons":[235],"end":[237],"did":[240,439],"not":[241,440],"differ":[242],"arms,":[245],"28%":[247],"30%":[254],"B":[259,304,374],"discontinued":[260],"reasons":[263],"toxicity.":[265],"Grade":[266],"3\u20134":[267,298],"toxicity":[268,282,443],"occurred":[269],"71.8%":[271,287],"81.9%":[275],"B,":[277,293],"p=0.0012).":[278],"Excluding":[279],"cetuximab-related":[280],"skin":[281,334,436],"resulted":[283],"similar":[285],"rates:":[286],"74.5%":[291],"p=0.40).":[294],"Most":[295],"frequent":[296],"grade":[297],"toxicities":[299],"vs":[303,308,312,316,320,325,330,337,388,400,410],"diarrhea":[306],"(19.2":[307],"25.8%),":[309],"fatigue":[310],"(12.6%":[311],"15.3%),":[313],"hypertension":[314],"(13.7%":[315],"8.8%),":[317],"nausea":[318],"(8.5":[319],"6.3%),":[321],"sensory":[322],"neuropathy":[323],"(9.6%":[324],"7.9%),":[326],"acneiform":[327],"rash":[328],"(0.5%":[329],"25.2%)":[331],"hand-foot":[333],"reaction":[335],"(18.4%":[336],"18.1%).":[338],"554":[342],"progressions":[343],"deaths":[345],"observed:":[347],"264":[348],"290":[353],"Median":[357],"10.7":[360],"(CI:":[362,370,386,390,397,403],"9.7;12.5)":[363],"9.8":[368],"8.6;10.7)":[371],"(p=0.019,":[375],"HR":[376],"1.22":[377],"(1.03;1.44).":[378],"rates":[380],"(PR":[381],"+":[382],"CR)":[383],"40.6%":[385],"34.5;46.9)":[387],"43.9%":[389],"37.8;50.1,":[391],"p=0.44":[392],"),":[393],"OS":[395],"20.4":[396],"18.1;26.1)":[398],"20.3":[401],"17.9;21.6,":[404],"p=0.21),":[405],"60-day":[407],"mortality":[408],"1.9%":[409],"2.4%.":[411],"Conclusions:":[412],"combination":[414],"both":[416],"antibodies,":[417],"bevacizumab,":[420],"CapOx":[422,445],"results":[423,449],"significant":[426,467],"decrease":[427],"compared":[430],"CapOx.":[434],"Besides":[435],"toxicity,":[437],"add":[441],"additional":[442],"bevacizumab.":[447],"Updated":[448],"will":[450],"be":[451],"presented":[452],"at":[453],"meeting,":[455],"including":[456],"data":[457],"on":[458],"KRAS":[459],"relation":[461],"outcome":[463],"No":[466],"financial":[468],"relationships":[469],"disclose.":[471]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1782669727","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
